Local, exendin-(9 - 39)-insensitive, site of action of GLP-1 in canine ileum

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 283, Issue 3 46-3, 2002, Pages

  Daniel, E E ^a,b,c,d   Anvari, M ^a,b,c,d   Fox Threlkeld, J E T ^a,b,c,d   McDonald, T J ^a,b,c,d  

^a Departments of Medicine Surgery   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Afferent nerves; Capsaicin; Gastric emptying; Intestinal motility; Paracrine action

Indexed keywords

ACETYLCHOLINE; CAPSAICIN; EXENDIN[9-39]; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HORMONE ANTAGONIST; N(G) NITROARGININE; TETRODOTOXIN; UNCLASSIFIED DRUG; VANILLOID RECEPTOR;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; ILEUM MUCOSA; INTESTINE INNERVATION; INTESTINE MOTILITY; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PYLORUS; SENSORY NERVE; STOMACH ANTRUM; STOMACH EMPTYING;

EID: 0036721115     PISSN: 01931857     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpgi.00110.2002     Document Type: Article

References (72)

1. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice
2. Extrinsic and intrinsic neural control of pyloric sphincter pressure in the dog
3. Comparison of the postprandial release of peptide YY and proglucagon-derived peptides in the rat
4. Effects of GLP-1 on gastric emptying, antropyloric motility and transpyloric flow in response to a non-nutrient liquid
5. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice
6. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats
7. Glucagon-like peptide-1 (7-36) amide as a novel neuropeptide
8. Coexistence of glicentin and peptide YY in colorectal L-cells in cat and man. An electron microscopic study
9. Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1
10. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse
11. Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons
12. Role of NO-related inhibition in intestinal function: Relation to vasoactive intestinal polypeptide (VIP)
13. Functional studies of nerve projections in the canine intestine
14. The tackykinin receptors inducing contractile responses of canine ileum circular muscle
15. Effect of chronic central administration of glucagon-like peptide-1 (7-36) amide on food consumption and body weight in normal and obese rats
16. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig
17. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity
18. Cloning and functional expression of the human glucagon-like peptide-1 (GLP-1) receptor
19. Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression
20. Minireview: The glucagon-like peptides
21. New developments in the biology of the glucagon-like peptides GLP-1 and GLP-2
22. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: Studies with the antagonist exendin 9-39
23. Glucagon-like peptide-1-(7-36) amide and peptide YY mediate intraduodenal fat-induced inhibition of acid secretion in dogs
24. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man
25. Substance P: A potent inhibitor of the canine small intestine in vivo
26. Exogenous opiates: Their local mechanisms of action in the canine small intestine and stomach
27. Activation of endogenous excitatory opiate pathways in the canine small intestine by field stimulation and motilin
28. Sites and mechanisms of action of neuropeptides on canine gastric motility differ in vivo and in vitro
29. The mechanisms of motilin excitation of the canine small intestine
30. Mechanisms of excitatory actions of neurotensin on canine small intestinal circular muscle in vivo and in vitro
31. Identification of mechanisms and sites of actions of mu and delta opioid receptor activation in the canine intestine
32. Stimulation of circular muscle motility of the isolated perfused canine ileum: Relationship to VIP output
33. Galanin inhibition of VIP release and circular muscle motility in the isolated perfused canine ileum
34. Pituitary adenylate cyclase-activating peptide as a neurotransmitter in the canine ileal circular muscle
35. Sites of nitric oxide (NO) actions in control of circular muscle motility of the perfused isolated canine ileum
36. Peptidergic regulation of gastrointestinal motility in rodents
37. Glucagon-like peptide-1-(7-36) amide and peptide YY mediate intraduodenal fat-induced inhibition of acid secretion in dogs
38. Glucagonlike peptide-1 (GLP-1) participation in ileal brake induced by intraluminal peptones in rat
39. Glucagon-like peptide (GLP-1) is involved in the central modulation of fecal output in rats
40. Different domains in the third intracellular loop of the GLP-1 receptor are responsible for Gα (s) and Gα (i)/Gα (o) activation
41. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum
42. Glucagonlike peptide 1: A newly discovered gastrointestinal hormone
43. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes
44. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms
45. Release of VIP and substance P from isolated perfused canine ileum
46. Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L 1 adipocytes
47. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men
48. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans
49. Glucagon-like peptide 1 (GLP-1): A potent gut hormone with a possible therapeutic perspective
50. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes
51. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans
52. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: Evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake
53. Distribution and immunocytochemical colocalization of peptide YY and enteroglucagon in endocrine cells of the rabbit colon
54. The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor
55. Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide
56. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide
57. Effects of intraduodenal glucose and fructose on antropyloric motility and appetite in healthy humans
58. Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats
59. Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans
60. Gastric emptying and release of incretin hormones after glucose ingestion in humans
61. Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1(7-36)amide in non-insulin dependent diabetes mellitus
62. Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling
63. Biological activity of GLP-1-analogues with N-terminal modifications
64. Comparison of the effect of native glucagon-like peptide 1 and dipeptidyl peptidase IV-resistant analogues on insulin release from rat pancreatic islets
65. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats
66. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: Effect mediated through central or enteric nervous mechanisms
67. Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin
68. Distribution of glucagon-like peptide I in canine and feline pancreas and gastrointestinal tract
69. Mechanisms of action of cholecystokinin in the canine gastrointestinal tract: Role of vasoactive intestinal peptide and nitric oxide
70. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow
71. Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1
72. Tissue-specific and glucose-dependent expression of receptor genes for glucagon and glucagon-like peptide-1 (GLP-1)